#9615 Phospho-(Ser) Kinase Substrate Antibody Sampler Kit
|Phospho-MAPK/CDK Substrates (PXS*P or S*PXR/K) (34B2) Rabbit mAb #2325||20 µl||WB, IP, IHC-P, E-P||H, All||Rabbit IgG|
|Phospho-(Ser) Arg-X-Tyr/Phe-X-pSer Motif Antibody #2981||20 µl||WB, IP, E-P||H, M, All||Rabbit|
|Phospho-(Ser) 14-3-3 Binding Motif (4E2) Mouse mAb #9606||20 µl||WB, IP, E-P||H, All||Mouse IgG1|
|Phospho-CDK Substrate Motif [(K/H)pSP] MultiMab™ Rabbit mAb mix #9477||20 µl||WB, IP, E-P||H, All||Rabbit IgG|
|Anti-rabbit IgG, HRP-linked Antibody #7074||100 µl||WB||Goat|
|Anti-mouse IgG, HRP-linked Antibody #7076||100 µl||WB||Horse|
Applications Key: W=Western Blotting, IP=Immunoprecipitation, IHC-P=Immunohistochemistry (Paraffin), E-P=Peptide ELISA (DELFIA)
Reactivity Key: H=Human, All=All Species Expected, M=Mouse
After the primary antibody is bound to the target protein, a complex with HRP-linked secondary antibody is formed. The LumiGLO® is added and emits light during enzyme catalyzed decomposition.
Western blot analysis of extracts from A431 cells, untreated or calyculin A-treated, using Phospho-(Ser) 14-3-3 Binding Motif (4E2) Mouse mAb (left) or Phospho-(Ser) 14-3-3 Binding Motif Antibody #9601 (right).
Western blot analysis of extracts from A431 cells, untreated or calyculin A treated, using Phospho-(Ser) Arg-X-Tyr/Phe-X-pSer Motif Antibody.
Western blot analysis of extracts from serum-starved A431 cells, untreated or treated in culture with EGF, and HeLa cells, untreated, hydroxyurea-treated (G1/S) or Nocodazole-treated (G2/M), using Phospho-MAPK/CDK Substrate (PXS*P or S*PXR/K) (34B2) Rabbit mAb.
Western blot analysis of extracts from COS-7 cells, synchronized in G1/S, G2/M, and G0 phase of the cell cycle, using
Phospho-CDK Substrate Motif [(K/H)pSP] MultiMab™ Rabbit mAb mix.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, control (left) or lambda phosphatase-treated (right), using Phospho-MAPK/CDK Substrates (PXS*P or S*PXR/K) (34B2) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human colon carcinoma, using Phospho-MAPK/CDK Substrate (PXS*P or S*PXR/K) (34B2) Rabbit mAb.
Phospho-(Ser) kinases and phosphatases play critical roles in a wide range of biological processes. Each phospho-(Ser) kinase phosphorylates serine within a specific motif. The MAPK and CDK families of serine protein kinases phosphorylate serine followed by proline residue (1-3). The consensus amino acid sequence for CDK substrate is (K/R)(S*)PX(K/R), where X denotes any one of the 20 amino acids and S* is the phosphorylation site (4-6). MAPK phosphorylates substrates with the concensus sequence PX(S*)P. The 14-3-3 proteins are a highly conserved family of proteins involved in the regulation of cell survival, apoptosis, proliferation and checkpoint control (7-11). Binding of 14-3-3 is mediated through phospho-serine-containing proteins (12). Two different phospho-serine containing motifs are found using a degenerate phospho-serine-oriented peptide library technique, RSXS*XP and RXY/FXS*XP (12). Motif 1 (Arg/Lys and Ser at positions -3 and -2, phospho-Ser at position 0, and Pro at position +2) is found in critical regulatory proteins including Bad, cdc25C, FoxO3A, PKC and c-Raf (11, 13). Motif 2 (RXY/FXS*XP) is found in critical regulatory proteins including cdc25A, cdc25B, PKCγ, IRS-1 and BCR (12). Although Phospho-(Ser) Arg-X-Tyr/Phe-X-pSer Motif Antibody binds 14-3-3 binding motif 2 with no requirement for proline in the +2 position, it provides a powerful tool for the discovery and characterization of potential 14-3-3 binding motif 2-containing proteins or other proteins with the RXY/FXS* motif. Antibodies specific to particular kinase substrates are invaluable reagents in determining kinase activity and identifying potential new kinase substrates. CST has developed antibodies that recognize phosphorylated serine within the context of a protein motif that is phosphorylated by MAPK/CDK, CDKs or 14-3-3. As shown by DELFIA or ELISA, each phospho-(Ser) kinase substrate antibody in this sampler kit is specific to its kinase substrate motif.
- Pearson, R.B. and Kemp, B.E. (1991) Methods Enzymol 200, 62-81.
- Karin, M. (1994) Curr Opin Cell Biol 6, 415-24.
- Lewis, T.S. et al. (1998) Adv Cancer Res 74, 49-139.
- Songyang, Z. et al. (1996) Mol Cell Biol 16, 6486-93.
- Songyang, Z. (1999) Prog Biophys Mol Biol 71, 359-72.
- Holmes, J.K. and Solomon, M.J. (1996) J Biol Chem 271, 25240-6.
- Aitken, A. (1995) Trends Biochem Sci 20, 95-7.
- Zha, J. et al. (1996) Cell 87, 619-28.
- Piwnica-Worms, H. (1999) Nature 401, 535, 537.
- Tzivion, G. et al. (1998) Nature 394, 88-92.
- Xing, H. et al. (2000) EMBO J 19, 349-58.
- Muslin, A.J. et al. (1996) Cell 84, 889-97.
- Yaffe, M.B. et al. (1997) Cell 91, 961-71.
Use of Cell Signaling Technology (CST) Motif Antibodies within certain methods (e.g., U.S. Patents No. 7,198,896 and 7,300,753) may require a license from CST. For information regarding academic licensing terms please have your technology transfer office contact CST Legal Department at CST_ip@cellsignal.com. For information regarding commercial licensing terms please contact CST Pharma Services Department at firstname.lastname@example.org.
MultiMab is a trademark of Cell Signaling Technology, Inc.
LumiGLO is a registered trademark of Kirkegaard & Perry Laboratories.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.